
## Snehal M Gaikwad

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4007595/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Developing Clinically Relevant Acquired Chemoresistance Models in Epithelial Ovarian Cancer Cell Lines. Bio-protocol, 2022, 12, e4310.	0.4	1
2	A Small Molecule Stabilizer of the MYC G4-Quadruplex Induces Endoplasmic Reticulum Stress, Senescence and Pyroptosis in Multiple Myeloma. Cancers, 2020, 12, 2952.	3.7	24
3	Hypomorphic mTOR Downregulates CDK6 and Delays Thymic Pre-T LBL Tumorigenesis. Molecular Cancer Therapeutics, 2020, 19, 2221-2232.	4.1	7
4	Mouse tumor susceptibility genes identify drug combinations for multiple myeloma. Journal of Cancer Metastasis and Treatment, 2020, 2020, .	0.8	2
5	Characterization of clinically used oral antiseptics as quadruplex-binding ligands. Nucleic Acids Research, 2018, 46, 2722-2732.	14.5	27
6	Soft drug-resistant ovarian cancer cells migrate via two distinct mechanisms utilizing myosin II-based contractility. Biochimica Et Biophysica Acta - Molecular Cell Research, 2018, 1865, 392-405.	4.1	22
7	Chemical and structural studies provide a mechanistic basis for recognition of the MYC G-quadruplex. Nature Communications, 2018, 9, 4229.	12.8	131
8	Abstract 5850: Nrf2-mediated oxidative stress response is altered during acquired resistance to the proteasome inhibitor, oprozomib, in multiple myeloma. , 2018, , .		0
9	Cooperative Targets of Combined mTOR/HDAC Inhibition Promote MYC Degradation. Molecular Cancer Therapeutics, 2017, 16, 2008-2021.	4.1	29
10	Abstract 194: Effective targeting of MYC expression with a novel nucleic acid binding (G4-quadruplex) small molecule coupled with HDAC inhibition synergizes to limit myeloma growth. , 2017, , .		0
11	A novel inhibitor of BCL2, Disarib abrogates tumor growth while sparing platelets, by activating intrinsic pathway of apoptosis. Biochemical Pharmacology, 2016, 122, 10-22.	4.4	18
12	Differential activation of NF-κB signaling is associated with platinum and taxane resistance in MyD88 deficient epithelial ovarian cancer cells. International Journal of Biochemistry and Cell Biology, 2015, 61, 90-102.	2.8	31
13	Magnetic nanoparticle-mediated hyperthermia therapy induces tumour growth inhibition by apoptosis and Hsp90/AKT modulation. International Journal of Hyperthermia, 2015, 31, 909-919.	2.5	34
14	IGF-1R inhibition potentiates cytotoxic effects of chemotherapeutic agents in early stages of chemoresistant ovarian cancer cells. Cancer Letters, 2014, 354, 254-262.	7.2	55
15	Non-Invasive Imaging of Phosphoinositide-3-Kinase-Catalytic-Subunit-Alpha (PIK3CA) Promoter Modulation in Small Animal Models. PLoS ONE, 2013, 8, e55971.	2.5	21
16	Non-invasive imaging of PI3K/Akt/mTOR signalling in cancer. American Journal of Nuclear Medicine and Molecular Imaging, 2012, 2, 418-31.	1.0	16